VIRAGEN EUROPE LTD
10-K405, EX-27, 2000-09-28
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: VIRAGEN EUROPE LTD, 10-K405, EX-23, 2000-09-28
Next: ITALY FUND INC, NT-NSAR, 2000-09-28



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                       4,945,063
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             5,201,775
<PP&E>                                       4,887,515
<DEPRECIATION>                                 896,417
<TOTAL-ASSETS>                               9,192,873
<CURRENT-LIABILITIES>                          847,216
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       196,621
<OTHER-SE>                                     423,344
<TOTAL-LIABILITY-AND-EQUITY>                 9,192,873
<SALES>                                              0
<TOTAL-REVENUES>                                16,752
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             6,367,534
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              22,491
<INCOME-PRETAX>                             (6,373,273)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (6,373,273)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (6,373,273)
<EPS-BASIC>                                      (0.37)
<EPS-DILUTED>                                    (0.37)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission